<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895943</url>
  </required_header>
  <id_info>
    <org_study_id>04_RVO-FNOs_2021</org_study_id>
    <nct_id>NCT04895943</nct_id>
  </id_info>
  <brief_title>Bariatric Endoscopy and NAFLD</brief_title>
  <official_title>Influence of Bariatric Endoscopy on Clinical Course of NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Find out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty&#xD;
      liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test and investigate the impact of bariatric endoscopy (various types of&#xD;
      intragastric balloons, endoscopic sleeve gastroplasty, aspiration therapy) on components of&#xD;
      the metabolic syndrome in obese patients, especially on influencing non-alcoholic steatosis&#xD;
      and steatohepatitis and signs of liver fibrotization and weight reduction. The method&#xD;
      consists of performing a mini-invasive endoscopic procedure and, as a result, reduced food&#xD;
      intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with NAFLD with degree of fibrosis of the liver among patients undergoing bariatric endoscopy and to determine the influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with NAFLD with degree of fibrosis of the liver among patients undergoing bariatric endoscopy and to determine the influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of bariatric endoscopy on change of weight</measure>
    <time_frame>24 months</time_frame>
    <description>Influence of bariatric endoscopy on change of weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of bariatric endoscopy on change of anthropometric parameters</measure>
    <time_frame>24 months</time_frame>
    <description>Influence of bariatric endoscopy on change of anthropometric parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric changes - weight (kg), BMI (kg/m2)</measure>
    <time_frame>24 months</time_frame>
    <description>Anthropometric changes - weight (kg), BMI (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric changes - waist and hip circumference (cm)</measure>
    <time_frame>24 months</time_frame>
    <description>Anthropometric changes - waist and hip circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional changes (eating habits) - questionnaire survey.</measure>
    <time_frame>24 months</time_frame>
    <description>Nutritional changes (eating habits) - questionnaire survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Components of the metabolic syndrome - blood pressure (mm/Hg)</measure>
    <time_frame>24 months</time_frame>
    <description>Components of the metabolic syndrome - blood pressure (mm/Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Components of the metabolic syndrome - waist circumference (cm)</measure>
    <time_frame>24 months</time_frame>
    <description>Components of the metabolic syndrome - waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Components of the metabolic syndrome - triacylglycerol levels (mmol/l), HDL cholesterol levels (mmol/l), glycemia (mmol/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Components of the metabolic syndrome - triacylglycerol levels (mmol/l), HDL cholesterol levels (mmol/l), glycemia (mmol/l)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>NAFLD</condition>
  <condition>Liver Steatosis</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group with adjustable IGB</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with non-adjustable IGB</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric endoscopy, mainly intragastric balloons, plication of the stomach too</intervention_name>
    <description>bariatric endoscopy, mainly intragastric balloons, plication of the stomach too</description>
    <arm_group_label>Group with adjustable IGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric endoscopy, mainly intragastric balloons, plication of the stomach too</intervention_name>
    <description>bariatric endoscopy, mainly intragastric balloons, plication of the stomach too</description>
    <arm_group_label>Group with non-adjustable IGB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obese patients undergoing bariatric endoscopy procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21-70 years&#xD;
&#xD;
          -  BMI &gt;27 Kg/m2&#xD;
&#xD;
          -  Must be able to comply with all study requirements for the duration of the study as&#xD;
             outlined in the protocol. This includes complying with the visit schedule as well as&#xD;
             study-specific procedures such as clinical assessment, endoscopy, radiography, as well&#xD;
             as laboratory investigations&#xD;
&#xD;
          -  Must be able to understand and be willing to provide written informed consent&#xD;
&#xD;
          -  Patient living within radio range 300 km from the study center&#xD;
&#xD;
          -  Failure of the cognitive-behavioral approach to weight reduction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following exclusionary criteria cannot be enrolled in the&#xD;
        study:&#xD;
&#xD;
          -  BMI &lt;27&#xD;
&#xD;
          -  History of gastric surgery.&#xD;
&#xD;
          -  Previous technical difficulties in gastric and duodenal endoscopy or inability to&#xD;
             perform endoscopy&#xD;
&#xD;
          -  History of GIT diseases such as achalasia, esophageal motility disorders, severe&#xD;
             esophagitis or gastritis, the recent history of ulcers, history of steatosis or&#xD;
             obstruction in the GIT&#xD;
&#xD;
          -  Proven celiac disease&#xD;
&#xD;
          -  Previous irreversible endoscopic procedures and surgical treatment of obesity&#xD;
&#xD;
          -  Chronic and acute pancreatitis&#xD;
&#xD;
          -  Active or chronic infectious hepatitis&#xD;
&#xD;
          -  Known liver disease or suspected PBC, PSC, autoimmune hepatitis, alpha1-antitrypsin&#xD;
             deficiency, Wilson's disease, hereditary hemochromatosis, known cirrhosis or history&#xD;
             of hepatic decompensation, AST or ALT&gt; 5-8x ULN&#xD;
&#xD;
          -  Type 1 or type 2 diabetes with insulin&#xD;
&#xD;
          -  History of malignant disease&#xD;
&#xD;
          -  Specific genetic or hormonal disorders associated with obesity (Prader-Willi syndrome,&#xD;
             MC4R mutations, etc.)&#xD;
&#xD;
          -  Serious disorders of blood clotting and hematopoiesis&#xD;
&#xD;
          -  Severe forms of psychiatric illness (endogenous depression, schizophrenia, suicidal&#xD;
             tendencies, psychosis)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP&gt; 150 mm Hg or diastolic BP&gt; 100 mm Hg) or&#xD;
             severe heart disease (severe cardiac dysfunction, etc.)&#xD;
&#xD;
          -  Serious autoimmune diseases or long-term use treated with glucocorticoids or&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Disorders of thyroid function unresponsive to processing.&#xD;
&#xD;
          -  Renal impairment with GFR &lt;60 ml / min / 1.73 m2, or albumin excretion&gt; 1000 mg / day&#xD;
&#xD;
          -  Substance use including excessive alcohol use (&gt; 21 units / week for men and&gt; 14 units&#xD;
             / week for women, - 1 unit (250ml 12 ° or 330ml 10 ° beer; 100ml wine; 25ml = small&#xD;
             spirits of spirits))&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Vašura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Adam Vašura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonín Bartusek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Blaho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jitka Macháčková, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019 Mar;15(3):502-511. doi: 10.1016/j.soard.2018.12.002. Epub 2018 Dec 6.</citation>
    <PMID>30683512</PMID>
  </reference>
  <reference>
    <citation>Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, Lopez-Nava G, Shikora S, Brooks J. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011 Oct;21(10):1499-507. doi: 10.1007/s11695-011-0424-z.</citation>
    <PMID>21553304</PMID>
  </reference>
  <reference>
    <citation>Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361. Review.</citation>
    <PMID>30122876</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>NAFLD</keyword>
  <keyword>liver steatosis</keyword>
  <keyword>liver fibrosis</keyword>
  <keyword>bariatric endoscopy</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers. The data may be provided upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

